- Trials with a EudraCT protocol (89)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
89 result(s) found for: Indacaterol.
Displaying page 1 of 5.
EudraCT Number: 2016-002113-21 | Sponsor Protocol Number: CQMF149G2202 | Start Date*: 2016-12-21 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, active-controlled, 2 week treatment, parallel-group study to assess the efficacy and safety of indacaterol acetate delivered via the Concept1 inhalation dev... | |||||||||||||
Medical condition: lung function effects of two doses of indacaterol acetate, 75 μg and 150 μg, in pediatric asthma patients 6-11 years old | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SK (Completed) BE (Completed) HU (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001825-25 | Sponsor Protocol Number: CIDD001A2201 | Start Date*: 2011-11-01 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-centre, randomized, double-blind, double-dummy, multiple-dose, crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol admi... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003127-11 | Sponsor Protocol Number: CQVA149A3401 | Start Date*: 2014-02-26 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A prospective, multicenter, 12-week, randomized open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms o.d.) or indacaterol maleate and glycopyrronium bromide fixed-d... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) LT (Completed) SK (Completed) BE (Completed) EE (Completed) LV (Completed) IE (Completed) SE (Completed) AT (Completed) PT (Completed) IT (Completed) GB (Completed) DK (Completed) GR (Completed) HU (Completed) PL (Completed) ES (Completed) DE (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000520-18 | Sponsor Protocol Number: CQMF149E2203 | Start Date*: 2012-10-18 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo controlled, 12-week treatment, parallel-group study to assess the efficacy, safety and pharmacokinetics of indacaterol acetate (75 and 150 μg o.d.) ... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SK (Completed) DE (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004169-41 | Sponsor Protocol Number: CQAB149B2329 | Start Date*: 2006-01-19 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 52-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d) in patients wi... | ||
Medical condition: Chronic obstructive pulmonary disease (COPD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-010589-46 | Sponsor Protocol Number: CQAB149D2301 | Start Date*: 2009-05-20 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-centre, randomized, double-blind, placebo controlled, multiple-dose, 4-way cross-over study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol... | |||||||||||||
Medical condition: persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013763-19 | Sponsor Protocol Number: CQAB149BIT01 | Start Date*: 2009-09-24 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: Multicenter, randomized, blinded, placebo controlled, cross over, single dose study to assess the effect of indacaterol (150 �g) versus tiotropium (18 �g) on Inspiratory Capacity in moderate COPD p... | |||||||||||||
Medical condition: moderate COPD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002899-25 | Sponsor Protocol Number: CQVM149B2302 | Start Date*: 2015-12-17 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, 52-week, double-blind, parallel-group, active-controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LT (Completed) DE (Completed) SK (Completed) PT (Completed) AT (Completed) HU (Completed) NL (Completed) FI (Completed) BE (Completed) ES (Completed) DK (Completed) LV (Completed) GR (Completed) FR (Completed) BG (Completed) IE (Completed) HR (Completed) SI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012600-48 | Sponsor Protocol Number: CQAB149B2222 | Start Date*: 2009-10-21 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, partially-blinded, single-dose, 4-way crossover study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol maleate administered via the Co... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007944-33 | Sponsor Protocol Number: CQAB149B2348 | Start Date*: 2009-03-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase IIIb multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150 μg o.d. vs inhaled tiotropium 18 μg o.d... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) FI (Completed) SK (Completed) CZ (Completed) LT (Completed) IS (Completed) BE (Completed) PT (Completed) EE (Completed) DK (Completed) LV (Completed) HU (Completed) DE (Completed) FR (Completed) NL (Completed) PL (Completed) GB (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003191-19 | Sponsor Protocol Number: CQMF149A2201 | Start Date*: 2007-10-25 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, multi-center, parallel group, double-blind, placebo and formetrol controlled 14 day dose ranging trial of 4 doses of indacaterol delivered via Twisthaler®, in adult and adolescent pa... | |||||||||||||
Medical condition: persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) ES (Completed) HU (Completed) GB (Completed) PL (Ongoing) SK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018481-22 | Sponsor Protocol Number: CQAB149B2223 | Start Date*: 2010-04-12 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, randomized, double-blind, placebo-controlled, parallel group, repeated-dose study to evaluate the efficacy, safety, tolerability and pharmacokinetics of three different dosing regim... | |||||||||||||
Medical condition: Persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001953-28 | Sponsor Protocol Number: 2012RC15 | Start Date*: 2013-08-20 | |||||||||||
Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside | |||||||||||||
Full Title: Proof of concept study to evaluate single and chronic dosing effects of ultra-long acting bronchodilator therapy on mannitol challenge in asthmatic patients taking inhaled corticosteroids | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000663-42 | Sponsor Protocol Number: CQAB149B2335SE | Start Date*: 2008-06-03 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A | |||||||||||||
Full Title: Extensión de 26 semanas del estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, con grupos paralelos y diseño adaptativo, de 26 semanas de tratamiento, para evaluar la segurid... | |||||||||||||
Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) DE (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004168-21 | Sponsor Protocol Number: CQAB149B2328 | Start Date*: 2006-01-30 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d.)... | ||
Medical condition: Chronic obstructive pulmonary disease (COPD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Prematurely Ended) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001762-14 | Sponsor Protocol Number: 69765 | Start Date*: 2020-07-29 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Evaluation of the anti-inflammatory effects of glycopyrronium added to indacaterol/mometasone on the allergen-induced late asthmatic response | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000473-12 | Sponsor Protocol Number: ULT01 | Start Date*: 2015-10-12 |
Sponsor Name:UMCG | ||
Full Title: The effectiveness of single dose Ultibro Breezhaler (indacaterol/glycopyrronium) by sd-DPI versus ipratropium/salbutamol by nebulizer in improving FEV1 and dyspnea during stable state of COPD | ||
Medical condition: COPD, chronic obstructive pulmonary disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003634-15 | Sponsor Protocol Number: CQAB149B2211 | Start Date*: 2006-09-13 | |||||||||||
Sponsor Name:NovartisPharma Services AG | |||||||||||||
Full Title: An exploratory, double-blind comparison of inspiratory capacity (IC) and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open-label b.i.d. administration o... | |||||||||||||
Medical condition: Mild to severe COPD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001954-28 | Sponsor Protocol Number: CQAB149B2334 | Start Date*: 2006-10-10 | |||||||||||
Sponsor Name:NovartisPharma Services AG | |||||||||||||
Full Title: A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.)... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) DK (Completed) HU (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) EE (Completed) LT (Completed) SE (Completed) LV (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001955-37 | Sponsor Protocol Number: CQAB149B2335S | Start Date*: 2007-04-29 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A | |||||||||||||
Full Title: Estudio multicéntrico, aleatorizado, doble ciego, doble enmascarado, controlado con placebo, con grupos paralelos y diseño adaptativo, de 26 semanas de tratamiento, para evaluar la eficacia, seguri... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
